MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-05-2024
Nektar Therapeutics Gross Profit 2011-2025 | NKTR
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Nektar Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 93.2 M | 1.17 B | 277 M | 135 M | 197 M | 172 M | 110 M | 50.8 M | 49.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.17 B | 49.6 M | 250 M |
Quarterly Gross Profit Nektar Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 623 K | 2.64 M | 501 K | -789 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.64 M | -789 K | 744 K |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADiTx Therapeutics
ADTX
|
-493 K | $ 3.05 | 4.81 % | $ 40.2 K |  USA |
 |
Aeterna Zentaris
AEZS
|
11 K | - | 5.93 % | $ 314 M |  Canada |
 |
Abeona Therapeutics
ABEO
|
925 K | $ 4.81 | -1.23 % | $ 103 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
1.02 B | $ 11.96 | 0.13 % | $ 3.7 B | USA |
 |
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | USA |
 |
argenx SE
ARGX
|
2.68 M | $ 901.39 | -1.59 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
823 K | $ 5.88 | 1.03 % | $ 212 M | USA |
 |
Achieve Life Sciences
ACHV
|
18.2 M | $ 4.69 | -1.88 % | $ 93 M | USA |
 |
BioDelivery Sciences International
BDSI
|
14 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.22 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | USA |
 |
Ascendis Pharma A/S
ASND
|
319 M | $ 206.12 | -1.18 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.36 | -1.95 % | $ 8.08 B |  Australia |
 |
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.12 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Baudax Bio
BXRX
|
-1.24 M | - | 0.59 % | $ 63 K | USA |
 |
AbbVie
ABBV
|
10.7 B | $ 226.39 | -1.0 % | $ 400 B | USA |
 |
ChemoCentryx
CCXI
|
64.9 M | - | - | $ 3.74 B | USA |
 |
Codiak BioSciences
CDAK
|
2.92 K | - | -55.98 % | $ 2.15 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
62.8 M | $ 15.13 | -13.34 % | $ 2.23 B | USA |
 |
BioLineRx Ltd.
BLRX
|
19.7 M | $ 3.37 | 3.47 % | $ 908 M |  Israel |
 |
Avid Bioservices
CDMO
|
7.32 M | - | - | $ 789 M | USA |
 |
Biogen
BIIB
|
12.4 B | $ 182.61 | 0.35 % | $ 26.6 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-2.55 M | - | - | $ 7.29 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.34 B | $ 53.01 | -1.51 % | $ 10.1 B | USA |
 |
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M | USA |
 |
Clovis Oncology
CLVS
|
123 M | - | -7.23 % | $ 13 M | USA |
 |
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | USA |
 |
Chimerix
CMRX
|
324 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
7.9 K | - | - | $ 401 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
371 M | $ 9.44 | -1.82 % | $ 611 M | USA |